LENZ Therapeutics
LENZ
63 hedge funds and large institutions have $81.5M invested in LENZ Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 10 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
8% more capital invested
Capital invested by funds: $75.8M → $81.5M (+$5.73M)
0.12% more ownership
Funds ownership: 7.53% → 7.65% (+0.12%)
6% less funds holding
Funds holding: 67 → 63 (-4)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $534K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.94M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.12M |
| 3 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.06M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.04M |
| 5 |
Renaissance Technologies
New York
|
+$747K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.55M |
| 2 |
NM
Newtyn Management
New York
|
-$1.35M |
| 3 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
-$453K |
| 4 |
AC
Aldebaran Capital
Carmel,
Indiana
|
-$322K |
| 5 |
D.E. Shaw & Co
New York
|
-$118K |
LENZ Hedge Fund Activity: Q4 2023 in Review
63 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q4 2023, worth a combined $81.5M — up 7.6% from $75.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LENZ and 8 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 22 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $1.94M. The largest seller was Citadel Advisors, cutting an estimated $1.55M.
- 63 institutional investors held LENZ Therapeutics (LENZ) as of Q4 2023, down from 67 in Q3 2023.
- Funds reported $81.5M of LENZ Therapeutics stock for Q4 2023, up 7.6% quarter-over-quarter.
- 8 funds opened new LENZ Therapeutics positions in Q4 2023 and 10 closed out, a net change of -2 holders.
- The largest LENZ Therapeutics buyer in Q4 2023 was Nantahala Capital Management, an estimated $1.94M added.
- The largest LENZ Therapeutics seller in Q4 2023 was Citadel Advisors, an estimated $1.55M sold.
Based on aggregated 13F filings for Q4 2023.